LYEL Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.41%, SMA50 -13.73%, SMA200 35.28%). The stock’s 14-day RSI is 44.72 (neutral), while the ATR of 2.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.87% below its high and over 200.78% above its low. Average 10-day trading volume of 101.13 thousand shares is in line with the 3-month average of 107.25 thousand, indicating normal recent market interest.

Lyell Immunopharma, Inc. has 19.21 million shares outstanding. The public float is 12.05 million shares, elevated short interest at 0.85% of float. This equals 132.97 thousand shares. The short ratio is 2.04 days. Institutional investors hold 62.96% of the float. Insiders own 20.56%. ARCH Venture Partners IX, LLC holds 1.43 million shares, ARCH Venture Fund XIII, L.P. has 1.43 million shares and Klausner Richard has 843.36 thousand shares. Over the past six months, insider transactions show net selling. They sold 14.27 thousand shares across 13 transactions.

Lyell Immunopharma, Inc. generated EPS of -$22.95 over the past year. Five-year average earnings growth is -19.9%. Wall Street analysts project EPS growth of 31.67% annually over the next five years. The latest quarter delivered EPS of -$2.13. The next quarter is forecast at -$2.37. Next year's EPS is expected at $10.18. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $10.00. The high target offers 123.44% upside. The low target suggests -50.35% downside. The mean target is $25.80. This offers 28.1% upside. Lyell Immunopharma, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -24.2%. The prior quarter beat by -23.95%. Over the last six quarters, Apple has recorded several small beats. These include -10.0% in August 07, 2024.

Lyell Immunopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.03. This means the shares are trading above this model’s fair value.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) closed at $20.14 USD, gaining $0.44 (2.23%) from the previous close of $19.70. The stock is currently mid-range between its 52-week high and low $7.65 and $45.00. With a market capitalization of about $469.40 million, Lyell Immunopharma, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.15). Key stats such as the average daily volume over the past year has been around 109.91 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Lyell Immunopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lynn Seely, the company employs approximately 300 people and listed since June 17, 2021. Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) shares are down -22.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Lyell Immunopharma, Inc. trading at a premium to the broader market with a P/E of -1.23. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $12.00, suggesting -40.42% downside. Our AI forecast model points to short-term weakness (-6.16% over two weeks), a medium-term fall (-38.63% over three months), and a longer-term loss (-46.92% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lyell Immunopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.16%, with price expected at $18.90 by April 07, 2026, within a range of $17.11 to $20.56 3-Month Outlook: Projected fall of -38.63%, reaching $12.36 by June 22, 2026, with a range of $10.64 to $13.81. 1-Year Outlook: Projected loss of -46.92%, with price at $10.69 by March 24, 2027, within a range of $7.26 to $14.35.

Lyell Immunopharma, Inc. trades at a P/E ratio of -1.23, slightly below the S&P 500 average, with a price-to-sales ratio of 12789.77 and a price-to-book ratio of 1.36 suggesting the stock is closer to book value. The P/FCF stands at -2.57, also above market averages.